Welcome to our dedicated page for Corvus Pharmaceu SEC filings (Ticker: CRVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) SEC filings page on Stock Titan provides access to the company’s public reports as filed with the U.S. Securities and Exchange Commission. Corvus is a Delaware-incorporated, clinical-stage biopharmaceutical company whose common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the Nasdaq Global Market. Its filings give structured detail on operations, risk factors, capital structure and governance as it advances immunotherapy programs for cancer and immune diseases.
Through this page, you can review current and periodic reports such as Forms 8-K, which Corvus uses to announce material events including financial results, business updates and board of director changes. For example, recent 8-K filings have furnished press releases on quarterly financial results and described the appointment of a new director to the Board and its committees.
Investors researching CRVS can also use this section to locate annual reports (Form 10-K) and quarterly reports (Form 10-Q), where available, which typically discuss the company’s clinical-stage pipeline, including the ITK inhibitor soquelitinib, the adenosine A2a receptor inhibitor ciforadenant and the anti-CD73 antibody mupadolimab. These filings often outline key clinical programs such as the registration Phase 3 trial in relapsed/refractory peripheral T cell lymphoma and trials in atopic dermatitis and Autoimmune Lymphoproliferative Syndrome.
Stock Titan enhances these documents with AI-powered summaries that highlight important sections, helping readers quickly identify information on clinical development, collaborations, equity structure and risk disclosures without reading every page. Real-time updates from EDGAR mean new CRVS filings, including any future Forms 4 related to insider transactions or proxy statements on executive and director compensation, can be reviewed promptly from a single, organized interface.
Corvus Pharmaceuticals, Inc. insider ownership is detailed in an amended Schedule 13G filing. As of December 31, 2025, Dr. Richard A. Miller is reported as the beneficial owner of 6,085,922 shares of common stock, or 7.8% of the class, based on 74,681,872 shares outstanding as of November 4, 2025.
Dr. Miller’s position includes 1,136,707 shares held directly, 1,188,103 shares held through the Miller-Horning Family Trust, and 3,761,112 shares underlying stock options that are vested or vest within 60 days of December 31, 2025. The Miller-Horning Family Trust and Dr. Sandra J. Horning each beneficially own 1,188,103 shares, representing 1.6% of the common stock.
Adams Street investment funds updated their ownership disclosure in Corvus Pharmaceuticals after a major stock offering. Adams Street Partners and affiliated funds now beneficially own 3,275,616 shares of Corvus common stock, representing 3.9% of the 83,767,650 shares outstanding as of January 23, 2026.
The change in percentage is reported as arising solely from Corvus’ underwritten public offering, in which the company sold 7,900,677 shares at $22.15 per share and an additional 1,185,101 shares through the underwriters’ option. The Adams Street reporting group states it has not traded Corvus shares in the past 60 days.
Corvus Pharmaceuticals director and 10% owner Peter A. Thompson reported multiple option exercises linked to OrbiMed-affiliated entities. On
An additional 8,609,091 shares of common stock are reported as indirectly owned through OrbiMed Private Investments V, LP and related OrbiMed entities. The filing states that Thompson, OrbiMed Advisors and OrbiMed Capital GP V LLC each disclaim beneficial ownership of these securities except to the extent of any pecuniary interest.
The Vanguard Group reported a passive ownership stake in Corvus Pharmaceuticals common stock. Vanguard disclosed beneficial ownership of 3,873,482 shares, representing 5.18% of the class as of December 31, 2025. Vanguard has shared voting power over 472,993 shares and shared dispositive power over all 3,873,482 shares, with no sole voting or dispositive power.
The shares are held for Vanguard’s investment clients, who are entitled to dividends and sale proceeds, and no single client holds more than 5% of the class. Vanguard also notes an internal realignment effective January 12, 2026, after which certain subsidiaries are expected to report beneficial ownership on a disaggregated basis.
Corvus Pharmaceuticals’ major shareholder OrbiMed filed an ownership update after Corvus completed an underwritten public offering of 7,900,677 common shares at $22.15 per share. Following this offering, OrbiMed Private Investments V, LP beneficially owns 8,609,091 shares, or about 10.3% of Corvus’s common stock, including pre-funded warrants for 1,444,085 shares.
The filing explains that OrbiMed’s ownership percentage fell by more than 1% due to the increase in Corvus’s shares outstanding, not due to share sales. A 45-day lock-up applies to director Peter Thompson and certain other insiders, limiting most share sales and registration demands after the offering.
Corvus Pharmaceuticals entered an underwriting agreement for an underwritten public stock offering of 7,900,677 shares of common stock at a public offering price of $22.15 per share. Underwriters agreed to buy the shares at $20.821 per share and were granted a 30‑day option to purchase an additional 1,185,101 shares, which they exercised in full on January 22, 2026. After underwriting discounts, commissions and estimated expenses and including the option shares, Corvus expects net proceeds of approximately $188.3 million. The company plans to use these funds for working capital and general corporate purposes, including capital expenditures, research and development for its Phase 3 T cell lymphoma and multiple Phase 2 dermatology and asthma trials, as well as sales, marketing and administrative expenses.
Corvus Pharmaceuticals, Inc. is offering 7,900,677 shares of common stock at $22.15 per share in an underwritten public offering on the Nasdaq Global Market. Underwriters also have a 30‑day option to buy up to 1,185,101 additional shares, implying gross proceeds of about $174.999,995.55 and underwriting discounts and commissions of $10,499,999.73, before expenses.
The company expects net proceeds of approximately $163.6 million, or $188.3 million if the option is fully exercised, and plans to use the cash mainly for working capital and research and development, including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa and asthma trials, plus sales, marketing and administrative expenses. Together with existing cash, cash equivalents and marketable securities, Corvus expects to fund operations into the first quarter of 2028.
Corvus recently reported positive Phase 1 cohort 4 data for soquelitinib in moderate to severe atopic dermatitis, showing a 72% mean reduction in EASI at day 56 versus 40% on placebo and higher EASI 75 and IGA 0/1 response rates, including in patients previously treated with systemic therapies. As of December 31, 2025, it preliminarily estimates cash, cash equivalents and marketable securities of about $56.7 million and has suspended its $100 million at‑the‑market program with Jefferies after selling no shares.
Corvus Pharmaceuticals is launching a $150 million primary offering of common stock and pre-funded warrants, plus an underwriters’ option for up to an additional $22.5 million of common stock. The pre-funded warrants are priced at the share offering price minus $0.0001 and are exercisable at $0.0001 per share, subject to ownership caps, and this prospectus also covers the shares issuable upon their exercise. Corvus reports positive Phase 1 data for soquelitinib in moderate to severe atopic dermatitis, with a 72% mean EASI reduction at day 56 versus 40% for placebo in cohort 4 and favorable safety. The company had approximately $56.7 million in cash, cash equivalents and marketable securities as of December 31, 2025 on a preliminary basis, and expects existing cash plus offering proceeds to fund operations into the first quarter of 2028, although it has disclosed substantial doubt about its ability to continue as a going concern without additional capital.
Corvus Pharmaceuticals, Inc. filed an update explaining that on January 20, 2026 it suspended sales under its Open Market Sale AgreementSM with Jefferies LLC. This at-the-market program had been established under a Form S-3 shelf registration and related August 6, 2024 prospectus supplement to permit sales of up to $100 million of ATM Shares of common stock. Before the suspension, no ATM Shares had been sold, so the full $100 million of ATM Shares remained available. The agreement with Jefferies remains in effect, but the company states it will not sell common stock under this program unless and until it files a new prospectus supplement or registration statement with the SEC.
Corvus Pharmaceuticals reported positive new data from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis. Patients receiving 200 mg twice daily for 56 days showed a mean 70% reduction in EASI scores, compared with 40% for placebo, and 75% achieved EASI 75 versus 20% on placebo. Responses deepened between days 28 and 56, with statistically significant separation at day 56 and activity seen even in patients previously treated with systemic therapies such as dupilumab and JAK inhibitors. Biomarker results support the drug’s ITK inhibition mechanism, indicating immune rebalancing across multiple T cell pathways. Safety in cohort 4 remained favorable, with only Grade 1–2 adverse events and no serious events. Based on these results, the company plans to start a Phase 2 trial in the first quarter of 2026.